ADAPY — Adaptimmune Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.60m
- $10.22m
- $178.03m
Adaptimmune Therapeutics PLC expected to post earnings of 14 cents a share - Earnings Preview
Brief: Adaptimmune Announces Appointment Of Cintia Piccina As Chief Commercial Officer
Brief: Data From Adaptimmune Trial Indicate Adding Akti To Manufacturing May Contribute To Sustained Antitumor Activity Of Next-Gen Spear T-Cells
Brief: Adaptimmune Reports Positive Results From Its Pivotal Trial In Patients With Synovial Sarcoma And MRCLS
Adaptimmune Therapeutics PLC reports results for the quarter ended in September - Earnings Summary
Brief: Adaptimmune Announces Overall Response Rate Of 36% In Its Cancers Clinical Trial
Adaptimmune jumps on deal with Roche to develop cancer therapies
Adaptimmune jumps on deal with Roche to develop cancer therapies
Brief: Adaptimmune Enters Into Strategic Collaboration With Genentech To Research, Develop, And Commercialize Cancer-Targeted Allogeneic T-Cell Therapies
Brief: Adaptimmune Enters Into Strategic Collaboration With Genentech
U.S. RESEARCH ROUNDUP-Bluebird Bio, Smiledirectclub, Whitehorse Finance
Adaptimmune Therapeutics PLC reports results for the quarter ended in June - Earnings Summary
Brief: Adaptimmune Reports Second Quarter Financial Results And Business Update
Adaptimmune Therapeutics PLC expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Virgin Galactic, Kohl's, Ralph Lauren, Tesla
U.S. STOCKS ON THE MOVE-Tesla, VBI Vaccines, Ralph Lauren, Virgin Galactic
Adaptimmune: Climbs on positive data from soft tissue cancer study
Brief: Adaptimmune Reports data from Phase 2 SPEARHEAD-1 Trial At ASCO
Adaptimmune Therapeutics PLC reports results for the quarter ended in March - Earnings Summary